{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:14:09Z","timestamp":1788286449379,"version":"build-2803163510"},"reference-count":36,"publisher":"Ordem dos Medicos","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Med Port"],"abstract":"<jats:p>Introdu\u00e7\u00e3o: O estudo nacional TREND-8 revelou altera\u00e7\u00f5es significativas nos padr\u00f5es de prescri\u00e7\u00e3o de medicamentos antidiab\u00e9ticos em Portugal entre 2017 e 2024, com aumentos marcados na utiliza\u00e7\u00e3o de inibidores do cotransportador s\u00f3dio-glicose tipo 2 (iSGLT2) e de agonistas do recetor do pept\u00eddeo semelhante ao glucagon tipo 1 (arGLP-1). O estudo TREND-8 REGIONS pretendeu analisar as diferen\u00e7as regionais e entre diferentes contextos de presta\u00e7\u00e3o de cuidados de sa\u00fade. M\u00e9todos: Este estudo nacional, transversal, seriado e retrospetivo analisou as prescri\u00e7\u00f5es de f\u00e1rmacos antidiab\u00e9ticos em Portugal entre 2017 e 2024, considerando o contexto de presta\u00e7\u00e3o de cuidados de sa\u00fade (cuidados de sa\u00fade prim\u00e1rios, hospitais p\u00fablicos e institui\u00e7\u00f5es privadas) e a regi\u00e3o geogr\u00e1fica (Norte, Centro, Lisboa, Alentejo, Algarve, Madeira e A\u00e7ores). Resultados: As biguanidas mantiveram-se como a classe de antidiab\u00e9ticos mais prescrita em todas as regi\u00f5es, apesar de existir um decl\u00ednio nacional uniforme na propor\u00e7\u00e3o de prescri\u00e7\u00e3o de 2,3%\/ano, representando 37,5% das prescri\u00e7\u00f5es em 2024. As prescri\u00e7\u00f5es de insulina evidenciaram um decl\u00ednio da propor\u00e7\u00e3o de prescri\u00e7\u00e3o (taxa anual -5,3%\/ano) em todas as regi\u00f5es, correspondendo a 7,5% das prescri\u00e7\u00f5es em 2024, com propor\u00e7\u00f5es significativamente inferiores na Madeira (5,5%; p &lt; 0,001). Os iSGLT2 registaram o maior aumento (34,5%\/ano), com diferen\u00e7as ligeiras na magnitude de crescimento entre regi\u00f5es. Esta classe atingiu 29,3% do total das prescri\u00e7\u00f5es em 2024, com propor\u00e7\u00f5es inferiores no Alentejo (27,5%; p = 0,002). Os arGLP-1 apresentaram o segundo maior aumento (24,1%\/ano), mais evidente no Alentejo (34,4%\/ano; p &lt; 0,001) e nos A\u00e7ores (38,4%\/ano; p &lt; 0,001), representando 4,9% das prescri\u00e7\u00f5es em 2024. Esta propor\u00e7\u00e3o foi superior nos A\u00e7ores (7,1%) e em Lisboa (5,6%) e inferior no Alentejo (4,0%), Centro (4,3%) e Madeira (4,4%) (p &lt; 0,05). Entre os diferentes contextos de presta\u00e7\u00e3o de cuidados de sa\u00fade, a prescri\u00e7\u00e3o de arGLP-1 aumentou de forma mais acentuada nos cuidados de sa\u00fade prim\u00e1rios (32,0%\/ano), mas foi nas institui\u00e7\u00f5es privadas que atingiu maior propor\u00e7\u00e3o de prescri\u00e7\u00e3o (10,4% das prescri\u00e7\u00f5es em 2024). O maior aumento na prescri\u00e7\u00e3o de iSGLT2 ocorreu nos cuidados de sa\u00fade prim\u00e1rios (35,4%\/ano), mas foi nos hospitais p\u00fablicos que estas terap\u00eauticas representaram maior propor\u00e7\u00e3o de prescri\u00e7\u00e3o (34,5%) em 2024. Conclus\u00e3o: De forma global, o estudo TREND-8 REGIONS demonstrou uma evolu\u00e7\u00e3o consistente com as recomenda\u00e7\u00f5es internacionais nas diferentes regi\u00f5es de Portugal e contextos assistenciais de sa\u00fade analisados entre 2017 e 2024, observando-se apenas uma ligeira variabilidade na prescri\u00e7\u00e3o dos arGLP-1.<\/jats:p>","DOI":"10.20344\/amp.24706","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:13:04Z","timestamp":1788279184000},"page":"528-538","source":"Crossref","is-referenced-by-count":0,"title":["Padr\u00f5es Regionais na Prescri\u00e7\u00e3o de Antidiab\u00e9ticos em Portugal: Oito Anos de Evid\u00eancia do Mundo Real (2017 - 2024) (Estudo TREND-8 REGIONS)"],"prefix":"10.20344","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4111-3787","authenticated-orcid":false,"given":"Ana Rita","family":"Leite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5886-2984","authenticated-orcid":false,"given":"C\u00e9lia","family":"Ramalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0738-9968","authenticated-orcid":false,"given":"Daniel","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafalda","family":"Marcelino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-8046","authenticated-orcid":false,"given":"Paula","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4201-9565","authenticated-orcid":false,"given":"Tiago","family":"Maricoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9287-4095","authenticated-orcid":false,"given":"S\u00f3nia","family":"Do Vale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Cal\u00e7ada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8173-8255","authenticated-orcid":false,"given":"Jo\u00e3o S\u00e9rgio","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8464","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"13468","doi-asserted-by":"crossref","unstructured":"Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400:1803-20.","DOI":"10.1016\/S0140-6736(22)01655-5"},{"key":"13469","doi-asserted-by":"crossref","unstructured":"Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133:2459-502.","DOI":"10.1161\/CIRCULATIONAHA.116.022194"},{"key":"13470","doi-asserted-by":"crossref","unstructured":"Preda A, Montecucco F, Carbone F, Camici GG, Luscher TF, Kraler S, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024;120:443-60.","DOI":"10.1093\/cvr\/cvae047"},{"key":"13471","doi-asserted-by":"crossref","unstructured":"Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14:361-77.","DOI":"10.1038\/s41581-018-0001-y"},{"key":"13472","doi-asserted-by":"crossref","unstructured":"Ferro EG, Michos ED, Bhatt DL, Lincoff AM, Elshazly MB. New decade, new FDA guidance for diabetes drug development: lessons learned and future directions. J Am Coll Cardiol. 2020;76:2522-6.","DOI":"10.1016\/j.jacc.2020.09.590"},{"key":"13473","unstructured":"American Diabetes Association Professional Practice Committee for D. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. Diabetes Care. 2026;49:S183-215."},{"key":"13474","doi-asserted-by":"crossref","unstructured":"Chong K, Chang JK, Chuang LM. Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. Kaohsiung J Med Sci. 2024;40:212-20.","DOI":"10.1002\/kjm2.12800"},{"key":"13475","doi-asserted-by":"crossref","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45:2753-86.","DOI":"10.2337\/dci22-0034"},{"key":"13476","doi-asserted-by":"crossref","unstructured":"Pottegard A, Andersen JH, Sondergaard J, Thomsen RW, Vilsboll T. Changes in the use of glucose-lowering drugs: a Danish nationwide study. Diabetes Obes Metab. 2023;25:1002-10.","DOI":"10.1111\/dom.14947"},{"key":"13477","doi-asserted-by":"crossref","unstructured":"Adhikari R, Jha K, Dardari Z, Heyward J, Blumenthal RS, Eckel RH, et al. National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020. J Am Heart Assoc. 2022;11:e023811.","DOI":"10.1161\/JAHA.121.023811"},{"key":"13478","doi-asserted-by":"crossref","unstructured":"Blood AJ, Chang LS, Colling C, Stern G, Gabovitch D, Zelle D, et al. Type 2 diabetes disease and management patterns across a large, diverse healthcare system: Issues and opportunities for guideline-directed therapies. Am Heart J. 2025;282:114-24.","DOI":"10.1016\/j.ahj.2025.01.003"},{"key":"13479","unstructured":"Scheen A. Agonistes des recepteurs du GLP-1 et diabete de type 2 : sous-utilisation paradoxale chez les patients avec maladie cardiovasculaire atheromateuse. Rev Med Liege. 2024;79:146-51."},{"key":"13480","unstructured":"Sociedade Portuguesa de Diabetologia - Observat\u00f3rio Nacional da Diabetes. Diabetes: factos e n\u00fameros 11.\u00aa edi\u00e7\u00e3o \u2014 os anos de 2022, 2023 e 2024. Lisboa: Sociedade Portuguesa de Diabetologia; 2025."},{"key":"13481","doi-asserted-by":"crossref","unstructured":"Moura AM, Martins SO, Raposo JF. Consumption of antidiabetic medicines in Portugal: results of a temporal data analysis of a thirteen-year study (2005-2017). BMC Endocr Disord. 2021;21:30.","DOI":"10.1186\/s12902-021-00686-w"},{"key":"13482","doi-asserted-by":"crossref","unstructured":"Neves JS, Leite AR, Marcelino M, Melo M, Freitas P, Ramalho C, et al. Trends in antidiabetic drug use in Portugal: 8 years real-world data from a nationwide retrospective observational study (2017-2024) (TREND-8 study). Diabetes Obes Metab. 2025;27:4022-8.","DOI":"10.1111\/dom.16429"},{"key":"13483","doi-asserted-by":"crossref","unstructured":"Cox DR. Interaction. Int Stat Rev. 1984;52:1.","DOI":"10.2307\/1403235"},{"key":"13484","doi-asserted-by":"crossref","unstructured":"Franzese R, Kam C. Modeling and interpreting interactive hypotheses in regression analysis. Ann Arbor, Michigan: University of Michigan Press; 2007.","DOI":"10.3998\/mpub.206871"},{"key":"13485","doi-asserted-by":"crossref","unstructured":"Efron B, Tibshirani RJ. An introduction to the bootstrap. London: Chapman and Hall\/CRC; 1994.","DOI":"10.1201\/9780429246593"},{"key":"13486","doi-asserted-by":"crossref","unstructured":"Hollander M, Wolfe DA, Chicken E. Nonparametric statistical methods. Wiley Series in Probability and Statistics. New York: Wiley; 2015.","DOI":"10.1002\/9781119196037"},{"key":"13487","doi-asserted-by":"crossref","unstructured":"Martinez-Camblor P, Perez-Fernandez S, Diaz-Coto S. The role of the p-value in the multitesting problem. J Appl Stat. 2020;47:1529-42.","DOI":"10.1080\/02664763.2019.1682128"},{"key":"13488","doi-asserted-by":"crossref","unstructured":"Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of Clinical Endocrinology Consensus Statement: comprehensive type 2 diabetes management algorithm - 2023 update. Endocr Pract. 2023;29:305-40.","DOI":"10.1016\/j.eprac.2023.02.001"},{"key":"13489","doi-asserted-by":"crossref","unstructured":"Alao S, Silva T, Leite AP, do Rosario M, Carvalho C, Coelho J, et al. Real-world evaluation of vascular complications and comorbidities in Portuguese patients with type 2 diabetes: results from the cMORE study. Rev Port Cardiol. 2024;43:669-79.","DOI":"10.1016\/j.repc.2024.04.011"},{"key":"13490","doi-asserted-by":"crossref","unstructured":"Volke V, Katus U, Johannson A, Toompere K, Heinla K, Runkorg K, et al. Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs. BMC Endocr Disord. 2022;22:251.","DOI":"10.1186\/s12902-022-01158-5"},{"key":"13491","doi-asserted-by":"crossref","unstructured":"Kostev K, Golz S, Scholz BM, Kaiser M, Pscherer S. Time to insulin initiation in type 2 diabetes patients in 2010\/2011 and 2016\/2017 in Germany. J Diabetes Sci Technol. 2019;13:1129-34.","DOI":"10.1177\/1932296819835196"},{"key":"13492","doi-asserted-by":"crossref","unstructured":"David B, Mezence J, Lange CR, Menges D, Carette C. Antidiabetic drugs consumption in france over a decade: an observational study. Clin Ther. 2025;47:371-6.","DOI":"10.1016\/j.clinthera.2025.02.005"},{"key":"13493","doi-asserted-by":"crossref","unstructured":"Hamblin PS, Earnest A, Russell AW, Talic S, Zomer E, Zoungas S. Utilization and cost of non-insulin glucose-lowering drugs in Australia from 2013 to 2023. Diabetes Obes Metab. 2024;26:4924-32.","DOI":"10.1111\/dom.15893"},{"key":"13494","doi-asserted-by":"crossref","unstructured":"Csatordai M, Benko R, Matuz M, Engi Z, Csupor D, Lengyel C, et al. Trends and regional differences in antidiabetic medication use: a nationwide retrospective observational study. Diabetol Metab Syndr. 2024;16:88.","DOI":"10.1186\/s13098-024-01334-8"},{"key":"13495","doi-asserted-by":"crossref","unstructured":"Alves L, Stringhini S, Barros H, Azevedo A, Marques-Vidal P. Inequalities in obesity in Portugal: regional and gender differences. Eur J Public Health. 2017;27:775-80.","DOI":"10.1093\/eurpub\/ckx041"},{"key":"13496","doi-asserted-by":"crossref","unstructured":"Costa E, Pestana J, Barros PP. Primary health care coverage in Portugal: the promise of a general practitioner for all. Hum Resour Health. 2024;22:55.","DOI":"10.1186\/s12960-024-00936-7"},{"key":"13497","unstructured":"Portal da Transpar\u00eancia do Sistema Nacional de Sa\u00fade. M\u00e9dia % total utentes com m\u00e9dico de fam\u00edlia atribu\u00eddo (2016-2025). [consultado 2026 jan 07]. Dispon\u00edvel em: https:\/\/transparencia.sns.gov.pt\/explore\/embed\/dataset\/utentes-inscritos-em-cuidados-de-saude-primarios\/analyze\/?disjunctive.ars&disjunctive.aces&sort=periodo&dataChart=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."},{"key":"13498","unstructured":"Instituto Nacional de Estat\u00edstica. Censos 2021. XVI recenseamento geral da popula\u00e7\u00e3o. VI recenseamento geral da habita\u00e7\u00e3o: resultados definitivos. [consultado 2026 jan 07]. Dispon\u00edvel em: https:\/\/www.ine.pt\/xurl\/pub\/65586079."},{"key":"13499","doi-asserted-by":"crossref","unstructured":"Car M, Erceg D, Udovicic M, Bokun T, Rahelic D. National utilization and expenditure trends of GLP-1 receptor agonists and dual GLP-1\/GIP agonist in Croatia, 2017-2024. Medicina. 2025;61:2210.","DOI":"10.3390\/medicina61122210"},{"key":"13500","doi-asserted-by":"crossref","unstructured":"Shirabe S, Yamazaki K, Oishi M, Arai K, Yagi N, Sato M, et al. Changes in prescription patterns and doses of oral antidiabetic drugs in Japanese patients with type 2 diabetes (JDDM70). J Diabetes Investig. 2023;14:75-80.","DOI":"10.1111\/jdi.13922"},{"key":"13501","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice C. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025;48:S181-206.","DOI":"10.2337\/dc25-S009"},{"key":"13502","doi-asserted-by":"crossref","unstructured":"Alkabbani W, Gamble JM. Prescribing trends of the sodium-glucose cotransporter-2 inhibitors among different physician specialties in Canada (2015-2021). Can J Diabetes. 2023;47:153-61.","DOI":"10.1016\/j.jcjd.2022.11.002"},{"key":"13503","unstructured":"Programa Nacional para a Diabetes. Programa nacional para a diabetes: desafios e estrat\u00e9gias 2024. 2024. [consultado 2026 fev 16]. Dispon\u00edvel em: https:\/\/www.dgs.pt\/programa-nacional-para-a-diabetes\/ficheiros-upload\/arquivo\/programa-nacional-para-a-diabetes-desafios-e-estrategias-2024-pdf.aspx?v=%3D%3DcgAAAB%2BLCAAAAAAABACztbV1KXd0dHRS8HF2hAAnR8eiyuAqz5KqsNBKC0Pf4pBQQ18XRzdHjyo317TsAJAancTcAmvytAIAtGvBFXIAAAA%3D."}],"container-title":["Acta M\u00e9dica Portuguesa"],"original-title":[],"link":[{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/download\/24706\/16016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/download\/24706\/16020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:29:01Z","timestamp":1788283741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/view\/24706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.20344\/amp.24706","relation":{},"ISSN":["1646-0758","0870-399X"],"issn-type":[{"value":"1646-0758","type":"electronic"},{"value":"0870-399X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}